Methyluracil rectal suppositories 0.5 g strip No. 10

Instructions for use Methyluracil rectal suppositories 0.5 g strip No. 10

Composition

active ingredient: methyluracil;

1 suppository contains 0.5 g of methyluracil;

excipient: solid fat.

Dosage form

Rectal suppositories.

Main physicochemical properties: suppositories are white or white with a yellowish or cream tint.

Pharmacotherapeutic group

Non-steroidal anabolic agents. ATC code A14B.

Pharmacological properties

Pharmacodynamics

The drug has anabolic and anticatabolic effects. Accelerates regeneration, wound healing, stimulates cellular and humoral immunity, has anti-inflammatory effects. A characteristic specific property of the drug is a stimulating effect on erythropoiesis and, especially, leukopoiesis.

Pharmacokinetics

When a suppository is administered rectally, the drug is well and almost completely absorbed through the mucosa and is detected in the blood after 20–30 minutes. The maximum concentration in the blood is reached after 1–2 hours. It is excreted from the body mainly by the kidneys in the form of metabolites and conjugates and partly with feces in unchanged form.

Indication

Inflammatory and ulcerative diseases of the lower parts of the large intestine: erosive and ulcerative colitis, proctosigmoiditis, anal fissures.

Contraindication

Hypersensitivity to methyluracil or to other components of the drug. The drug is contraindicated in acute and chronic (usually myeloid) forms of leukemia, lymphogranulomatosis, malignant bone marrow diseases.

Interaction with other medicinal products and other types of interactions

Methyluracil enhances the effect of strophanthin, increases the effectiveness of antibiotics and sulfonamide drugs.

Application features

Methyluracil is advisable to prescribe for mild forms of leukopenia. In cases of moderate severity of the disease, the drug should be taken only after the restoration of impaired blood cell regeneration. In severe forms of hematopoietic damage, methyluracil should not be prescribed.

Use during pregnancy or breastfeeding

The drug is not used during pregnancy or breastfeeding.

Ability to influence reaction speed when driving vehicles or other mechanisms

Until the patient's individual reaction to the drug is determined, one should refrain from driving or operating other mechanisms, given that during treatment with methyluracil, such adverse reactions from the nervous system as dizziness are possible.

Method of administration and doses

Remove the suppository from the blister pack and administer rectally. Adults and children over 14 years of age take 1 suppository 1–4 times a day. The course of treatment is from 7 days to 4 months, depending on the nature of the disease.

Children

The drug should not be used to treat children under 14 years of age.

Overdose

Not observed.

Side effects

From the side of the central nervous system: headache, dizziness.

Skin and subcutaneous tissue disorders: allergic reactions, including hyperemia, itching, skin rashes, urticaria.

Changes at the injection site: when inserting a suppository into the rectum, a short-term burning sensation and itching are sometimes felt.

Expiration date

2 years.

Storage conditions

In original packaging at a temperature not exceeding 15 °C.

Keep out of reach of children.

Packaging

5 suppositories in a strip. 2 strips in a cardboard pack.

Vacation category

Without a prescription.

Producer

PJSC "Monpharm".

Address

Ukraine, 19161, Cherkasy region, Uman district, Avramivka village, Zavodska st., 8.